| Biomarker ID | 1520 |
| PMID | 25168616 |
| Year | 2014 |
| Biomarker | PCA3 |
| Biomarker Basis | Concentration Based (ng/mL) |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Upregulated in Prostate Cancer |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways include: Proteins Involved in Prostate Cancer |
| Experiment | Prostate Cancer Vs No Cancer |
| Type of Biomarker | Diagnostic |
| Cohort | 708 men were included in the study. 589 with No cancer and 119 with Prostate cancer were chosen. In the range PSA >3 ng/ml, there were total of 202 patients. 162 did not have cancer and 40 did |
| Senstivity | NA |
| Specificity | NA |
| AUC | PSA > 3ng/ml Range: 0.62 (95% CI: 0.52–0.73);Full Cohort: 0.63 (95% CI: 0.58–0.69) |
| Accuracy | NA |
| Level Of Significance | PSA >3ng/ml: p=0.01; All Patients: p<0.01 |
| Method Used | NA |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |